TNF Pharmaceuticals (TNFA) announced a collaboration with Renova Health using AI and machine learning technologies to identify high-risk patient groups for studies of isomyosamine, aimed at preserving muscle mass during GLP-1 treatment. The partnership analyzes data from 30,000 patients to optimize recruitment and accelerate isomyosamine drug development. Renova’s platform identifies patient subsets based on underlying conditions, acute events, and medication profiles.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNFA: